Clinical efficacy of sarcubatrixartan combined with metoprolol tablets in patients with chronic heart failure
Objective:To explore the therapeutic effects of combination therapy with sarcubatrixartan and metoprolol tartrate tablets in patients with chronic heart failure.Methods:Using a random table method,82 patients with chronic heart failure admitted to our hospital from June 2021 to June 2023 were randomly divided into control and treatment groups,with 41 patients in each group.The control group was administered metoprolol tartrate tabletsorally at a dose of 6.25mg/time,twice a day.On the base of the control group,the treatment group received oral administration of sarcubatrixartan 100mg/time,twice a day.The treatment course for both groups was four weeks,and the therapeutic effects of the two groups were analyzed.The changes in cardiac function[left ventricular ejection fraction(LVEF),cardiac output(CO),and stroke volume(SV),6-minute walking distance(6MWT),levels of N-terminal pro-natriuretic peptide(NT-proBNP),intercellular adhesion molecule-1(ICAM-1),and interleukin-6(IL-6),as well as SCHF1 score,Lee's heart failure score,and MLHFQ score between the two groups before and after treatment were compared.Results:The total efficacy rate in the treatment group was higher than that in the control group(P＜0.05).There were no statistically significant differences in LVEF,CO,and SV between the two groups before treatment(P＞0.05).After treatment,LVEF,CO,and SV in both groups were higher than before treatment(P＜0.05).After treatment,the LVEF,CO,and SV in the treatment group were higher than those in the control group(P＜0.05).There was no statistically significant difference in 6MWT between the two groups before treatment(P＞0.05).After treatment,the 6MWT scores of both groups were higher than those before treatment(P＜0.05).The 6MWT score of the treatment group was higher than that of the control group after treatment(P＜0.05).There were no statistically significant differences in the levels of NT-proBNP,ICAM-1,and IL-6 between the two groups before treatment(P＞0.05).After treatment,the serum NT-proBNP,ICAM-1,,and IL-6 levels in both groups were lower than those before treatment(P＜0.05).Serum levels of NT-proBNP,ICAM-1,and IL-6 in the treatment group were lower than those in the control group after treatment(P＜0.05).There was no statistically significant difference in the SCHFI score,Lee's heart failure score,or MLHFQ score between the two groups before treatment(P＞0.05).After treatment,the SCHFI scores of both groups were higher than those before treatment,while the Lee's heart failure and MLHFQ scores were lower than those before treatment(P＜0.05).After treatment,the SCHFI score of the treatment group was higher than that of the control group,while Lee's heart failure and MLHFQ scores were lower than those of the control group(P＜0.05).Conclusions:The combination of sarcubatrixartan and metoprolol tartrate tablets had a significant therapeutic effect on patients with chronic heart failure,improving their cardiac function,enhancing their exercise endurance,reducing the levels of NT-proBNP,ICAM-1,and IL-6,and improving their quality of life.
万方数据
维普
